ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
Roquefort Therapeutics PLC (PK)

Roquefort Therapeutics PLC (PK) (ROQAF)

0.05
0.00
(0.00%)
마감 07 2월 6:00AM

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

가격
0.05
매수가
0.0001
매도가
88.05
거래량
-
0.00 일간 변동폭 0.00
0.049 52주 범위 0.1034
market_cap
전일 종가
0.05
개장가
-
최근 거래 시간
마지막 거래 시간
재정 규모
-
VWAP
-
평균 볼륨(3m)
-
발행 주식
129,149,998
배당수익률
-
주가수익률
-1.74
주당순이익(EPS)
-0.01
매출
200k
순이익
-1.75M

Roquefort Therapeutics PLC (PK) 정보

섹터
Cmp Integrated Sys Design
산업
Cmp Integrated Sys Design
웹사이트
본부
London, Gbr
설립됨
-
Roquefort Therapeutics PLC (PK) is listed in the Cmp Integrated Sys Design sector of the OTC 시장 with ticker ROQAF. The last closing price for Roquefort Therapeutics (PK) was US$0.05. Over the last year, Roquefort Therapeutics (PK) shares have traded in a share price range of US$ 0.049 to US$ 0.1034.

Roquefort Therapeutics (PK) currently has 129,149,998 shares in issue. The market capitalisation of Roquefort Therapeutics (PK) is US$6.46 million. Roquefort Therapeutics (PK) has a price to earnings ratio (PE ratio) of -1.74.

ROQAF 최신 뉴스

No news to show yet.
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10000000CS
40000000CS
120000000CS
26-0.01-16.66666666670.060.060.0492500.0496CS
52-0.0534-51.64410058030.10340.10340.0491440.05533846CS
156-0.07-58.33333333330.120.120.04943300.11805866CS
260-0.07-58.33333333330.120.120.04943300.11805866CS

ROQAF - Frequently Asked Questions (FAQ)

What is the current Roquefort Therapeutics (PK) share price?
The current share price of Roquefort Therapeutics (PK) is US$ 0.05
How many Roquefort Therapeutics (PK) shares are in issue?
Roquefort Therapeutics (PK) has 129,149,998 shares in issue
What is the market cap of Roquefort Therapeutics (PK)?
The market capitalisation of Roquefort Therapeutics (PK) is USD 6.46M
What is the 1 year trading range for Roquefort Therapeutics (PK) share price?
Roquefort Therapeutics (PK) has traded in the range of US$ 0.049 to US$ 0.1034 during the past year
What is the PE ratio of Roquefort Therapeutics (PK)?
The price to earnings ratio of Roquefort Therapeutics (PK) is -1.74
What is the cash to sales ratio of Roquefort Therapeutics (PK)?
The cash to sales ratio of Roquefort Therapeutics (PK) is 15.67
What is the reporting currency for Roquefort Therapeutics (PK)?
Roquefort Therapeutics (PK) reports financial results in GBP
What is the latest annual turnover for Roquefort Therapeutics (PK)?
The latest annual turnover of Roquefort Therapeutics (PK) is GBP 200k
What is the latest annual profit for Roquefort Therapeutics (PK)?
The latest annual profit of Roquefort Therapeutics (PK) is GBP -1.75M
What is the registered address of Roquefort Therapeutics (PK)?
The registered address for Roquefort Therapeutics (PK) is 85 GREAT PORTLAND STREET, FIRST FLOOR, LONDON, W1W 7LT
What is the Roquefort Therapeutics (PK) website address?
The website address for Roquefort Therapeutics (PK) is www.roquefortplc.com
Which industry sector does Roquefort Therapeutics (PK) operate in?
Roquefort Therapeutics (PK) operates in the CMP INTEGRATED SYS DESIGN sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
PRSTPresto Automation Inc (CE)
US$ 0.0005
(49,900.00%)
612.3k
SHMPNaturalShrimp Incorporated (CE)
US$ 0.0003
(29,900.00%)
2.07M
EFTReFFECTOR Therapeutics Inc (CE)
US$ 0.0002
(19,900.00%)
1.02k
WHENWorld Health Energy Holdings Inc (PK)
US$ 0.00015
(14,900.00%)
300k
EEGUFEmpire Energy Group Ltd (PK)
US$ 0.14
(12,627.27%)
10k
TRSIDTrophy Resources Inc
 0.005
(-99.93%)
144k
PTPLFPT Puradelta Lestari TBK (PK)
US$ 0.0111
(-99.89%)
5k
MAPTMAPtelligent Inc (CE)
US$ 0.000001
(-99.67%)
10k
ALEAFAleafia Health Inc (GM)
US$ 0.000001
(-99.00%)
25.04k
CNDLCandlewood Hotel Co Inc (CE)
US$ 0.000001
(-99.00%)
2.9k
RDARRaadr Inc (PK)
US$ 0.0007
(-17.65%)
528.35M
PHILPHI Group Inc (PK)
US$ 0.00015
(-25.00%)
488.66M
AFFUAffluence Corp (PK)
US$ 0.0005
(25.00%)
298.99M
GRLFGreen Leaf Innovations Inc (PK)
US$ 0.00015
(-25.00%)
282.58M
ABQQAB International Group Corporation (PK)
US$ 0.0004
(-11.11%)
173.6M
Horseman Country Horseman Country 5 분 전
Looking forward to playing another Toby Keith song upon the Twins' release!!!

"How Do You Like Me Now??!!!"

🚀🚀🚀💰💰💰🙌🙌🙌🙌
FNMA
esi23 esi23 5 분 전
So you are saying 0001 tomorrow?   
RITE
extrinsic55 extrinsic55 5 분 전
SGBX ask 1.02 ClimbDay1WatchForPopEarlyHoursTomorrow
SGBX
double_m double_m 6 분 전
So the 'revenue' from selling 'shares,' NOT EVs, is being used to pay off their lawsuits?!!! 🤣🤣🤣 What a f'kng business model!

💩Mullen Automotive!💩
💩 David Michery, CEO! 💩
💩 Board of Directors!💩
MULN
extrinsic55 extrinsic55 6 분 전
SGBX ask 1.02 ClimbDay1WatchForPopEarlyHoursTomorrow
SGBX
Mr Stockboy Mr Stockboy 6 분 전
Can a generic copy a patented capsulation if its novel invention is to protect an interior product if the standard of quality is essential to the efficacy of a drug? Amarin has never protected its own patented capsulation which is a d-shame for severe hyper-triG let alone CVD. Not being challenged,
AMRN
georgie18 georgie18 6 분 전
KZIA...$1.55... 🥳...https://schrts.co/QpVScFSV...Looking for Triple Bottom Bounce...Open Gap filled from the $2.60 Range Spike...3 Million Range Float...
KZIA
$Money Bags$ $Money Bags$ 6 분 전
Yeah, this is one of the oddest loadings I've seen in 30+ yrs of playing the otc.  No definite catalyst.  Selling into the bid has all but dried up.  The board is quiet, no real rumblings or tip offs that usually come with a p&d.  Just patient loading.
UATG
georgie18 georgie18 7 분 전
KZIA...$1.55... 🥳...https://schrts.co/QpVScFSV...Looking for Triple Bottom Bounce...Open Gap filled from the $2.60 Range Spike...3 Million Range Float...
KZIA
extrinsic55 extrinsic55 7 분 전
SGBX ask 1.02 ClimbDay1WatchForPopEarlyHoursTomorrow
SGBX
georgie18 georgie18 7 분 전
KZIA...$1.55... 🥳...https://schrts.co/QpVScFSV...Looking for Triple Bottom Bounce...Open Gap filled from the $2.60 Range Spike...3 Million Range Float...
KZIA
georgie18 georgie18 7 분 전
KZIA...$1.55... 🥳...https://schrts.co/QpVScFSV...Looking for Triple Bottom Bounce...Open Gap filled from the $2.60 Range Spike...3 Million Range Float...
KZIA
Scotty9 Scotty9 7 분 전
Who would buy this old ripoff
TNXP
ddls ddls 7 분 전
2/6/25, Buy: 5,000,000, Neutral: 321,000, Sell: 55,300...😭
BIEL
farooq farooq 7 분 전
So more downgrades came today. It will be above 10 again in 2 Weeks
F
Kool Aid Man Kool Aid Man 8 분 전
The more verifiable evidence someone presents to regulators the easier it is to interest and involve them. Tying bad actors to other frauds and scams helps as well as they like casting a broad net. Lastly, consider if any possible misdeeds might fall under the authority of multiple "3 letter agencie
SPZI
ShawnP123 ShawnP123 8 분 전
Looks like Tesla is moving away from Nvidia.
https://finance.yahoo.com/news/tesla-dojo-elon-musks-big-170000683.html
NVDA
DewDiligence DewDiligence 8 분 전
Recent Biotech Buyouts of Publicly Traded Companies

[Added ALMS-SLRN.]

Table entries are in descending order of buyout premium.
Reverse-mergers are listed at the bottom. [pre]
Acquired ‡Premium *Deal iHub
Company Buyer to Market
ABBV ABT ABUS
price_and_volume price_and_volume 8 분 전
Amended 8-K.

https://www.otcmarkets.com/filing/html?id=18165099&guid=o30-knmVG-GTh3h
...Within 120 days of the Closing Date, Seller will apply to FINRA to change its name from HUMBL, Inc., Previously 60 days as mentioned.
HMBL
GrandAdmiralThrawn GrandAdmiralThrawn 9 분 전
A merger. That’s the word on the street.
k9narc k9narc 9 분 전
Tofu taco night.
So easy to make, and it doubles as chili.



https://investorshub.advfn.com/uimage/uploads/2025/2/6/zdxbh09e8d220-86c5-4df7-a0aa-de02f7a2a655.jpg
winstocksnew winstocksnew 9 분 전
I was wrong. It was this company: http://nmcinc.com/web/

It all sounds good except the $.0 shown on the books.

I am still 100% behind Rite. They KEEP their promisss. 18 months is not a long time to wait.
RITE
BurgerKing82 BurgerKing82 9 분 전
Well,today sucked. Right when ya think it's turning a corner lol
HLLK
DewDiligence DewDiligence 9 분 전
ALMS acquires SLRN for $2.35/sh* in stock—a 24% premium to today’s 4:00pm closing price:

https://www.globenewswire.com/news-release/2025/02/06/3022460/0/en/Alumis-and-ACELYRIN-to-Merge-Creating-a-Late-Stage-Clinical-Biopharma-Company-Dedicated-to-Innovating-Developing-and-Commercializ

최근 히스토리

Delayed Upgrade Clock